CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on treatments for obesity and metabolic diseases [2]. Group 3: Allegations - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Group 4: Stock Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].